Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34–44.

Article  CAS  PubMed  Google Scholar 

Wada H, Asakura H, Okamoto K, Iba T, Uchiyama T, Kawasugi K, et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010;125:6–11.

Article  CAS  PubMed  Google Scholar 

Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.

Article  PubMed  PubMed Central  Google Scholar 

Takezako N, Sekiguchi N, Nagata A, Homma C, Takezako Y, Noto S, et al. Recombinant human thrombomodulin in the treatment of acute myeloid leukemia patients complicated by disseminated intravascular coagulation: retrospective analysis of outcomes between patients treated with heparin and recombinant human thrombomodulin therapy. Thromb Res. 2015;136:20–3.

Article  CAS  PubMed  Google Scholar 

Yamakawa K, Ohbe H, Taniguchi K, Matsui H, Fushimi K, Yasunaga H. Time trends of the outcomes and treatment options for disseminated intravascular coagulation: a nationwide observational study in Japan. JMA J. 2020;3:313–20.

PubMed  PubMed Central  Google Scholar 

Hisamune R, Mochizuki K, Yamakawa K. Real-world evidence on disseminated intravascular coagulation from Japan. Acute Med Surg. 2023;10: e836.

Article  PubMed  PubMed Central  Google Scholar 

Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: can it be predicted and prevented? Leuk Res. 2020;94: 106356.

Article  CAS  PubMed  Google Scholar 

Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25:1128–34.

Article  CAS  PubMed  Google Scholar 

McClellan JS, Kohrt HE, Coutre S, Gotlib JR, Majeti R, Alizadeh AA, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97:133–6.

Article  PubMed  PubMed Central  Google Scholar 

Silva WFD Jr, Rosa LID, Marquez GL, Bassolli L, Tucunduva L, Silveira DRA, et al. Real-life outcomes on acute promyelocytic leukemia in Brazil—early deaths are still a problem. Clin Lymphoma Myeloma Leuk. 2019;19:e116–22.

Article  PubMed  Google Scholar 

Humphries JE, Hess CE, Stewart FM. Acute promyelocytic leukemia: impact of hemorrhagic complications on response to induction chemotherapy and survival. South Med J. 1990;83:1157–61.

Article  CAS  PubMed  Google Scholar 

Huang YT, Liu XF, Fu RF, Chen YF, Liu W, Xue F, et al. Clinical evaluation of Chinese disseminated intravascular coagulation scoring system (version 2017) in patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2018;39:480–4.

CAS  PubMed  Google Scholar 

Uchiumi H, Matsushima T, Yamane A, Doki N, Irisawa H, Saitoh T, et al. Prevalence and clinical characteristics of acute myeloid leukemia associated with disseminated intravascular coagulation. Int J Hematol. 2007;86:137–42.

Article  PubMed  Google Scholar 

Naitoh M, Andoh K, Sadakata H, Tanaka H, Kobayashi N. Prediction of disseminated intravascular coagulation in patients with leukemia. Intern Med. 1994;33:131–5.

Article  CAS  PubMed  Google Scholar 

Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma. Int J Hematol. 2015;102:413–9.

Article  CAS  PubMed  Google Scholar 

Sase T, Wada H, Yamaguchi M, Ogawa S, Kamikura Y, Nishikawa M, et al. Haemostatic abnormalities and thrombotic disorders in malignant lymphoma. Thromb Haemost. 2005;93:153–9.

Article  CAS  PubMed  Google Scholar 

Jia J, Song Y, Lin N, Liu W, Ping L, Zheng W, et al. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. Ann Hematol. 2016;95:2023–31.

Article  CAS  PubMed  Google Scholar 

Yamashita S, Murakami C, Izumi Y, Sawada H, Yamazaki Y, Yokota TA, et al. Severe chronic active Epstein-Barr virus infection accompanied by virus-associated hemophagocytic syndrome, cerebellar ataxia and encephalitis. Psychiatry Clin Neurosci. 1998;52:449–52.

Article  CAS  PubMed  Google Scholar 

Tapazoglou E, Shah I. Disseminated intravascular coagulation and plasma cell leukemia. JAMA. 1983;250:2792.

Article  CAS  PubMed  Google Scholar 

Takahashi T, Suzukawa M, Akiyama M, Hatao K, Nakamura Y. Systemic AL amyloidosis with disseminated intravascular coagulation associated with hyperfibrinolysis. Int J Hematol. 2008;87:371–4.

Article  PubMed  Google Scholar 

Osone S, Fukushima K, Yano M, Kakazu M, Sano H, Kato Y, et al. Supportive care for hemostatic complications associated with pediatric leukemia: a national survey in Japan. Int J Hematol. 2019;110:743–50.

Article  CAS  PubMed  Google Scholar 

Mori H, Harada-Shirado K, Kawano N, et al. Net reclassification index in comparison of prognostic value of disseminated intravascular coagulation diagnostic criteria by Japanese Society on Thrombosis and Hemostasis and International Society on Thrombosis and Haemostasis: a multicenter prospective cohort study. Thromb J. 2023;21:84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Avvisati G, ten Cate JW, Büller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989;2:122–4.

Article  CAS  PubMed  Google Scholar 

Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112–7.

Article  CAS  PubMed  Google Scholar 

Brown JE, Olujohungbe A, Chang J, Ryder WD, Morganstern GR, Chopra R, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol. 2000;110:1010–2.

Article  CAS  PubMed  Google Scholar 

Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31–41.

Article  CAS  PubMed  Google Scholar 

Wada H, Japanese Society of Thrombosis Hemostasis/DIC subcommittee; Okamoto K, Iba T, Kushimoto S, Kawasugi K, Gando S, et al. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res. 2014; 134:924–5.

Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, et al. Impact of recombinant soluble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation. Thromb Res. 2013;131:436–43.

Article  CAS  PubMed  Google Scholar 

Asakura H, Takahashi H, Tsuji H, Matsushita T, Ninomiya H, Honda G, et al. Post-marketing surveillance of thrombomodulin alfa, a novel treatment of disseminated intravascular coagulation—safety and efficacy in 1,032 patients with hematologic malignancy. Thromb Res. 2014;133:364–70.

Article  CAS  PubMed  Google Scholar 

Matsushita T, Watanabe J, Honda G, Mimuro J, Takahashi H, Tsuji H, et al. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort. Thromb Res. 2014;133:772–81.

Article  CAS  PubMed  Google Scholar 

Yoshinobu S, Honda G, Kawano N, Uchiyama T, Kawasugi K, Madoiwa S, et al. Clinical features of disseminated intravascular coagulation according to the French-American-British Classification in patients with acute leukemia and thrombomodulin alfa treatment-a cohort study using a postmarketing surveillance database. Clin Appl Thromb Hemost. 2021;27:10760296211054094.

Article  CAS  PubMed  PubMed Central